QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, May 28, 2008, 28(22):5784-5793; doi:10.1523/JNEUROSCI.1146-08.2008

This Article Full Text Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Richard, K. L. Articles by Rivest, S. Search for Related Content PubMed PubMed Citation Articles by Richard, K. L. Articles by Rivest, S.

 Previous Article  |  Next Article 

Development/Plasticity/Repair
Toll-Like Receptor 2 Acts as a Natural Innate Immune Receptor to Clear Amyloid β_1–42 and Delay the Cognitive Decline in a Mouse Model of Alzheimer's Disease

Karine L. Richard, Mohammed Filali, Paul Préfontaine, and Serge Rivest

Laboratory of Molecular Endocrinology, Centre hospitalier de l'Université Laval Research Center, and Department of Anatomy and Physiology, Laval University, Québec, Québec, Canada G1V 4G2

Correspondence should be addressed to Dr. Serge Rivest, Laboratory of Molecular Endocrinology, Centre hospitalier de l'Université Laval Research Center, and Department of Anatomy and Physiology, Laval University, 2705 Laurier Boulevard, Québec, Québec, Canada G1V 4G2. Email: serge.rivest{at}crchul.ulaval.ca

Microglia are the immune cells of the brain, they are activated in the brain of Alzheimer's disease (AD) patients and mouse models of AD, and they express the innate immune receptor toll-like receptor 2 (TLR2). The present study investigated role of this receptor in the progression of AD-like pathologies. Here we show that amyloid β (Aβ) stimulates TLR2 expression in a small proportion of microglia. We then generated triple transgenic mice that are deficient in TLR2 from mice that harbor a mutant human presenelin 1 and a chimeric mouse/human amyloid precursor protein (APP) genes. TLR2 deficiency accelerated spatial and contextual memory impairments, which correlated with increased levels of Aβ_1–42 and transforming growth factor β1 in the brain. NMDA receptors 1 and 2A expression levels were also lower in the hippocampus of APP–TLR2^–/– mice. Gene therapy in cells of the bone marrow using lentivirus constructs expressing TLR2 rescued the cognitive impairment of APP–TLR2^–/– mice. Indeed, lenti-green fluorescent protein/TLR2 treatment had beneficial effects by restoring the memory consolidation process disrupted by TLR2 deficiency in APP mice. These data suggest that TLR2 acts as an endogenous receptor for the clearance of toxic Aβ by bone-marrow-derived immune cells. The cognitive decline is markedly accelerated in a context of TLR2 deficiency. Upregulating this innate immune receptor may then be considered as a potential new powerful therapeutic approach for AD.

Key words: bone marrow stem cells; inflammation; innate immunity microglia; neuroprotection; postsynaptic receptors; transforming growth factor β1

---

Received Dec. 17, 2007; revised April 10, 2008; accepted April 14, 2008.

Correspondence should be addressed to Dr. Serge Rivest, Laboratory of Molecular Endocrinology, Centre hospitalier de l'Université Laval Research Center, and Department of Anatomy and Physiology, Laval University, 2705 Laurier Boulevard, Québec, Québec, Canada G1V 4G2. Email: serge.rivest{at}crchul.ulaval.ca

This article has been cited by other articles:

				L. K. Erdman, G. Cosio, A. J. Helmers, D. C. Gowda, S. Grinstein, and K. C. Kain CD36 and TLR Interactions in Inflammation and Phagocytosis: Implications for Malaria J. Immunol., November 15, 2009; 183(10): 6452 - 6459. [Abstract] [Full Text] [PDF]

				Y. Doi, T. Mizuno, Y. Maki, S. Jin, H. Mizoguchi, M. Ikeyama, M. Doi, M. Michikawa, H. Takeuchi, and A. Suzumura Microglia Activated with the Toll-Like Receptor 9 Ligand CpG Attenuate Oligomeric Amyloid {beta} Neurotoxicity in in Vitro and in Vivo Models of Alzheimer's Disease Am. J. Pathol., November 1, 2009; 175(5): 2121 - 2132. [Abstract] [Full Text] [PDF]

				E. G. Reed-Geaghan, J. C. Savage, A. G. Hise, and G. E. Landreth CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar A{beta}-Stimulated Microglial Activation J. Neurosci., September 23, 2009; 29(38): 11982 - 11992. [Abstract] [Full Text] [PDF]

				V. Boissonneault, M. Filali, M. Lessard, J. Relton, G. Wong, and S. Rivest Powerful beneficial effects of macrophage colony-stimulating factor on {beta}-amyloid deposition and cognitive impairment in Alzheimer's disease Brain, April 1, 2009; 132(4): 1078 - 1092. [Abstract] [Full Text] [PDF]

				H. Scholtzova, R. J. Kascsak, K. A. Bates, A. Boutajangout, D. J. Kerr, H. C. Meeker, P. D. Mehta, D. S. Spinner, and T. Wisniewski Induction of Toll-Like Receptor 9 Signaling as a Method for Ameliorating Alzheimer's Disease-Related Pathology J. Neurosci., February 11, 2009; 29(6): 1846 - 1854. [Abstract] [Full Text] [PDF]

				S. Jimenez, D. Baglietto-Vargas, C. Caballero, I. Moreno-Gonzalez, M. Torres, R. Sanchez-Varo, D. Ruano, M. Vizuete, A. Gutierrez, and J. Vitorica Inflammatory Response in the Hippocampus of PS1M146L/APP751SL Mouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic J. Neurosci., November 5, 2008; 28(45): 11650 - 11661. [Abstract] [Full Text] [PDF]

				A. A. Babcock, H. Toft-Hansen, and T. Owens Signaling through MyD88 Regulates Leukocyte Recruitment after Brain Injury J. Immunol., November 1, 2008; 181(9): 6481 - 6490. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help